問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Search Result

Search Result

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

廖斌志

Recruiting

List

252Cases

2021-09-01 - 2025-03-31

Phase I/II

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2025-09-01 - 2033-05-31

Phase III

Not yet recruiting
A RANDOMIZED, PHASE 3, OPEN-LABEL STUDY TO EVALUATE PF-08046054/SGN-PDLlV VERSUS DOCETAXEL IN ADULT PARTICIPANTS WITH PREVIOUSLY-TREATED PROGRAMMED CELL DEATH LIGAND 1 (PD-Ll) POSITIVE NON-SMALL-CELL LUNG CANCER (NSCLC)

  • Condition/Disease

    Non-small Cell Carcinoma 、Non-Small Cell Lung Cancer Metastatic、 Non-Small Cell Lung Carcinoma

  • Test Drug

    Injectables

Participate Sites
6Sites

Recruiting6Sites

2025-08-20 - 2029-02-17

Phase III

Active
AN OPEN-LABEL, RANDOMIZED, CONTROLLED PHASE 3 STUDY OF SIGVOTATUG VEDOTIN IN COMBINATION WITH PEMBROLIZUMAB COMPARED WITH PEMBROLIZUMAB MONOTHERAPY AS FIRST-LINE TREATMENT IN PARTICIPANTS WITH PD-L1 HIGH (≥50% OF TUMOR CELLS EXPRESSING PD-L1), LOCALLY ADVANCED, UNRESECTABLE, OR METASTATIC NON-SMALL CELL LUNG CANCER (BE6A LUNG-02)

  • Condition/Disease

    Non-Small Cell Lung Cancer、 Carcinoma, Non-Small-Cell Lung 、Carcinoma, Non-Small-Cell Lung (NSCLC)

  • Test Drug

    Frozen Crystal Injection Injection

Participate Sites
8Sites

Recruiting8Sites

2021-06-01 - 2024-02-27

Phase I/II

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting3Sites

Terminated2Sites

2024-03-01 - 2028-06-30

Phase I/II

Active
A Phase 1b/2, Open-label Study of Amivantamab Monotherapy and Amivantamab in Addition to Standard of Care Therapeutic Agents in Participants with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

  • Condition/Disease

    Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

  • Test Drug

    Amivantamab Paclitaxel Pembrolizumab Carboplatin

Participate Sites
5Sites

Recruiting5Sites

2025-10-01 - 2029-12-31

Phase III

Active
A Phase 3, Randomized, Open-Label, Multicenter Study of Amivantamab in Addition to Carboplatin and Pembrolizumab, Compared to Standard of Care Platinum and Pembrolizumab and 5-FU, in Participants with Treatment-Naive Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

  • Condition/Disease

    Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)

  • Test Drug

    Subcutaneous injection Injection Injection Injection Injection

Participate Sites
7Sites

Recruiting7Sites

2022-01-31 - 2028-09-30

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2023-05-01 - 2026-06-30

Phase II

Active
Subcutaneous Methotrexate, Oral Dexamethasone or Oral Montelukast for the Prevention of Infusion Related Reaction Associated with Amivantamab, an EGFR-MET bispecific antibody, Among Post-osimertinib Treated EGFRm NSCLC; SKIPPirr, a Phase 2 Study

  • Condition/Disease

    NSCLC

  • Test Drug

    N/A

Participate Sites
7Sites

Recruiting7Sites

2021-11-01 - 2026-06-30

Phase III

Active
A Phase 3, Open-Label, Randomized Study of Amivantamab and Lazertinib in Combination with Platinum-Based Chemotherapy Compared with Platinum-Based Chemotherapy in Patients with EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer After Osimertinib Failure.

  • Condition/Disease

    NSCLC

  • Test Drug

    JNJ-61186372 (Amivantamab)JNJ-73841937 (Lazertinib)

Participate Sites
8Sites

Not yet recruiting5Sites

Recruiting2Sites

Terminated1Sites

2018-12-30 - 2024-12-31

Phase I

Completed
A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of JNJ-61186372, a Human Bispecific EGFR and cMet Antibody, in Subjects With Advanced Non-Small Cell Lung Cancer

  • Condition/Disease

    Advanced Non-Small Cell Lung Cancer

  • Test Drug

    JNJ-61186372、Lazertinib (JNJ-73841937)

Participate Sites
7Sites

Not yet recruiting1Sites

Recruiting6Sites

夏德椿
China Medical University Hospital-Taipei

未分科

羅永鴻
Taipei Veterans General Hospital

Division of Thoracic Medicine

1 2 3 4 5 26
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB